CORRESPONDENCE

Letter to the Editor
Dear Sir,
We have read with interest the recent report by Kaufman et al. 1 of a patient who was reported to have a visual field defect develop 13 months following initiation of therapy with tiagabine. The visual field defect was reported to have reversed on discontinuation of therapy. It is important that these results be evaluated critically because if valid, they imply that the well-documented visual field defect induced by vigabatrin is a class effect of compounds that raise levels of GABA in the central nervous system. However, we believe that there is insufficient evidence in the Kaufman et al. 1 report to support such a conclusion for the reasons given below.
It is recognized by glaucoma specialists that a visual field defect should be replicated at least once prior to any consideration of initiation of therapeutic intervention 2, 3 . In a large study of ocular hypertensive patients, over 80% of new onset visual field defects could not be replicated on the next examination 4 . In addition, every major multicenter clinical trial in glaucoma (AGIS, CIGTS, EMGT, NTG, OHTS) has found it necessary to require replication of the development or progression of visual field loss on at least three consecutive visual fields in order to distinguish true changes from long-term variability 5 . The test-retest or long-term variability for automated threshold static perimetry is well documented [6] [7] [8] [9] and it can be quite considerable. This variability also increases with eccentricity in the visual field [7] [8] [9] . For suprathreshold static visual field screening procedures, like those used in the Kaufman et al. 1 study, the long term variability is even greater 10 .
The Kaufman et al. 1 study reports that a patient receiving tiagabine developed visual field defects consisting of missed stimuli in the outer rim of points in the far peripheral nasal visual field of both eyes. Compared to the initial examination, the number of missed points increased by six in the right eye and ten in the left eye. This is certainly well within the expected test-retest variability for suprathreshold static visual field screening procedures 10 . In addition to variability, there are many other factors that can produce pseudo visual field loss in the far periphery. Apparent constriction of the visual field can also be caused by decreased attention and fatigue 11 , refractive error 12 and trial lens rim artifacts 13 . The cooperation and reliability of the patient can also influence visual field test results. The present study does not provide information pertaining to fixation losses, false positive and false negative responses during the test. Finally, selection of inappropriate parameters in the Humphrey 120 point visual field screening test can add further spurious variability to measured performance. Specifically, the instrument presents target stimuli at 6 dB above a threshold that can either be age determined or determined by an estimate of central threshold at the beginning of the test. If the latter procedure is used, then changes in number of points missed can be due to a fluctuation in the target luminance used rather than a true change in patient sensitivity Given all of these factors, we believe that the authors' report of a tiagabine induced visual field defect that reverses with drug withdrawal is not strongly supported by the data provided. A more thorough study did not find any visual field defects in 15 epileptic patients on tiagabine monotherapy 14 . A more likely basis for the reported visual field changes in the current study is test-retest variability, which can occur from a variety of sources as described earlier. 
